在患有异常性帕金森病的患者中开发定量残疾评估工具
Han Gil Seo1, Seo Jung Yun1, Yoojin Song2
1Department of Rehabilitation Medicine, Seoul National University College of Medicine, Seoul National University Hospital, Seoul 03080, Republic of Korea.
Diagnostics (Basel, Switzerland)
|September 28, 2024
概括
这项研究开发了一种新的工具,用于测量异常性帕金森病 (IPD) 患者的残疾,并考虑其波动的"开启"和"关闭"状态. 这种新的方法准确地反映了日常生活的挑战,改善了IPD的残疾评估.
科学领域:
- 神经学 神经学
- 康复医学 康复医学 康复医学
- 生物医学工程 生物医学工程
背景情况:
- 异常性帕金森病 (IPD) 显著影响日常生活和功能独立性.
- 对IPD中残疾的准确定量评估对于有效的管理和治疗至关重要.
- 现有的评估工具可能无法充分捕捉IPD症状的动态性质,特别是"开关"现象.
研究的目的:
- 开发和验证一种新的定量性残疾评估工具,用于患有特异性帕金森病 (IPD) 的患者.
- 将"开关"现象纳入IPD患者的残疾测量.
- 将新工具的有效性与已建立的尺度进行比较,例如修改的施瓦布和英格兰日常生活活动尺度 (mSEADL) 和韩国修改的巴特尔指数 (K-MBI).
主要方法:
- 从两个医院招募了47名IPD患者.
- 使用修改后的施瓦布和英格兰日常生活活动量表 (mSEADL) 和韩国修改后的巴特尔指数 (K-MBI) 进行比较.
- 开发了一种新的定量残疾测量公式,考虑了"开启"和"关闭"状态和清醒时间: ((mSEADL开启 × 开启时间) + (mSEADL关闭 × 关闭时间)) / 清醒时间).
主要成果:
- 超过一半的参与者 (51.1%) 在清醒时段经历了"非状态".
- 在"州外"的mSEADL分数明显低于"州内" (p < 0.05).
- 新型残疾测量显示与mSEADL (0.960) 和K-MBI (0.808) 的高相关性,表明强大的有效性 (p < 0.05).
结论:
- IPD患者经常经历"开启-关闭"现象,导致在"关闭状态"期间的依赖性增加.
- "开关"现象是IPD残疾评估中需要考虑的关键因素.
- 本研究开发的新型定量残疾评估工具为评估IPD患者残疾提供了更准确和更全面的方法.
相关概念视频
Parkinson's Disease: Treatment
233
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
233
Parkinson's Disease: Overview
492
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
492


